Julianne Hough is the new face of Revance’s Botox rival Daxxify. | Julianne Hough is the new face of Revance’s Botox rival ...
Revance, a global aesthetics, regenerative and consumer skincare company, is proud to announce world renowned dancer, actress ...
Revance is proud to unveil "Here for It All," a new campaign for PanOxyl, that celebrates the brand's commitment to supporting people throughout their skincare journey with trusted, real-life ...
NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ...
Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. (NASDAQ:RVNC). Under the terms of the agreement, Crown will commence ...
Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery
- Results show DaxibotulinumtoxinA for Injection (DAXI) can reduce frown lines for 24 weeks (approximately 6 months) or more - This manuscript presents the findings from SAKURA 1 and 2 side-by-side, ...
The total U.S. therapeutic neuromodulator market opportunity for Daxxify is $2.5 billion, including $345 million in cervical dystonia specifically, Revance said. (Ismail Rajo/Getty Images) After ...
Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced results from its Phase 2 ...
Shares of Revance Therapeutics surged 18% Thursday after the company announced the Food and Drug Administration had approved Daxxify, a facial injection drug that Revance hopes will challenge Botox’s ...
Dec 9 (Reuters) - Crown Laboratories would buy the anti-wrinkle injection maker Revance Therapeutics (RVNC.O), opens new tab at a roughly 50% lower price compared to an original agreement signed in ...
Shares of Revance Therapeutics (RVNC +0.00%) are up by a respectable 15.8% as of 11:08 a.m. EDT Wednesday morning. The biopharma's stock is regaining some of its lost ground after yesterday's ...
NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results